Decoding ALS: Clinical Insights from a 56-Year-Old Male Case

Netra Agarwal, Savitran Eshwar

Abstract


Amyotrophic Lateral Sclerosis (ALS) is an obliterating neurodegenerative disorder characterized by the progressive degeneration of motor neurons within the brain and spinal cord. This leads to extreme muscle weakness, atrophy, and eventually, paralysis. The disease ordinarily shows in people between the ages of 40 and 70, though it can occur at any age. Early symptoms often incorporate muscle jerking, cramping, and stiffness, beside weakness in the arms or legs. As ALS advances, it essentially impedes the patient's capacity to speak, swallow, and breathe, necessitating comprehensive care.   The precise cause of ALS remains elusive, with a combination of hereditary and natural factors believed to contribute to its onset. Whereas familial cases account for around 10% of ALS incidences, the larger part are sporadic with no clear familial connection. In spite of extensive research, there's as of now no cure for ALS, and treatment basically centers on indication administration and progressing the patient's quality of life. This incorporates a multidisciplinary approach including physical treatment, occupational therapy, nutritional support, respiratory care, and, in a few cases, medication to slow disease progression.   Given the tenacious progression and fatal nature of ALS, early diagnosis and intercession are vital. Continuous research is crucial to reveal the underlying mechanisms and develop more viable medicines, advertising hope for superior management and, eventually, a remedy for this debilitating disease. Keywords: Motor Neuron Degeneration | Reinnervation | Neurogenic Changes | Fasciculations | Chronic Denervation | Reduced Recruitment PatternsBackground: Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of motor neurons. 

Keywords


Keywords: Motor Neuron Degeneration | Reinnervation | Neurogenic Changes | Fasciculations | Chronic Denervation | Reduced Recruitment Patterns Background: Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by the

Full Text:

PDF

References


Brown, R. H., & Al-Chalabi, A. (2017). Amyotrophic Lateral Sclerosis. *The New England Journal of Medicine, 377*(2), 162-172. https//doi.org/10.1056/NEJMra1603471.

van Es, M. A., Hardiman, O., Chio, A., Al-Chalabi, A., Pasterkamp, R. J., Veldink, J. H., & van den Berg, L. H. (2017). Amyotrophic Lateral Sclerosis. *The Lancet, 390*(10107), 2084-2098. https//doi.org/10.1016/S0140-6736(17)31287-4.

Taylor, J. P., Brown, R. H., & Cleveland, D. W. (2016). Decoding ALS: From Genes to Mechanism. *Nature, 539*(7628), 197-206. https//doi.org/10.1038/nature20413.

Ghasemi, M., Brown, R. H., & Garbern, J. Y. (2021). Genetics of Amyotrophic Lateral Sclerosis. *Cold Spring Harbor Perspectives in Medicine, 8*(2), a024125. https://doi.org/10.1101/cshperspect.a024125.

Chio, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., & Traynor, B. G. (2009). Prognostic Factors in ALS: A Critical Review. *Amyotrophic Lateral Sclerosis, 10*(5-6), 310-323. https//doi.org/10.3109/17482960903211272.

Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012). Riluzole for Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND). *Cochrane Database of Systematic Reviews, 3*. https://doi.org/10.1002/14651858.CD001447.pub3.

Abe, K., Aoki, M., Tsuji, S., Itoyama, Y., Sobue, G., Yasuda, N., ... & Yoshino, H. (2014). Safety and Efficacy of Edaravone in Well Defined Patients with Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial. *Lancet Neurology, 16*(7), 505-512. https://doi.org/10.1016/S1474-4422(17)30115-1.

Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., ... & Zoing, M. C. (2011). Amyotrophic Lateral Sclerosis. *The Lancet, 377*(9769), 942-955. https://doi.org/10.1016/S0140-6736(10)61156-7.

Ludolph, A. C., Lücking, C. H., & Kassubek, J. (2012). MRI-Based Neuroimaging in ALS. *Current Opinion in Neurology, 25*(5), 524-529. https://doi.org/10.1097/WCO.0b013e328357a1bc.

Talbot, K. (2009). Motor Neuron Disease: The Bare Essentials. *Practical Neurology, 9*(5), 303-309. https//doi.org/10.1136/jnnp.2009.183541.

Strong, M. J., Abrahams, S., Goldstein, L. H., Woolley, S., McLaughlin, P., Snowden, J., ... & Turner, M. R. (2017). Amyotrophic Lateral Sclerosis – Frontotemporal Spectrum Disorder (ALS-FTSD): Revised Diagnostic Criteria. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18*(3-4), 153-174. https//doi.org/10.1080/21678421.2016.1267768.

Byrne, S., Walsh, C., Lynch, C., Bede, P., Elamin, M., Kenna, K., ... & Hardiman, O. (2011). Rate of Deterioration in Amyotrophic Lateral Sclerosis: A Clinic Population-Based Study. *Journal of Neurology, Neurosurgery & Psychiatry, 82*(6), 640-646. https://doi.org/10.1136/jnnp.2010.223750.

Renton, A. E., Chio, A., & Traynor, B. J. (2014). State of Play in Amyotrophic Lateral Sclerosis Genetics. *Nature Neuroscience, 17*(1), 17-23. https://doi.org10.1038/nn.3584.

Gordon, P. H., Miller, R. G., & Moore, D. H. (2004). ALS Care and Clinical Trials: Does Site Matter? *Journal of Neurology, Neurosurgery & Psychiatry, 75*(5), 756-760. https://doi.org/10.1136/jnnp.2003.028407.

Brooks, B. R. (1994). El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. *Journal of the Neurological Sciences, 124*(1), 96-107. https://doi.org/10.1016/0022-510X(94)90191-0.

Benatar, M., Wuu, J., McLean, R., Andersson, P., & Tremblay, J. P. (2016). The Benefit of Dual Drug Therapy in ALS: A Study of Riluzole and Sodium Phenylbutyrate Combined. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17*(5-6), 294-301. https://doi.org/10.3109/21678421.2016.1161372.

Nijssen, J., Comley, L. H., & Hedlund, E. (2017). Motor Neuron Vulnerability and Resistance in Amyotrophic Lateral Sclerosis. *Acta Neuropathologica, 133*(6), 863-885. https://doi.org/10.1007/s00401-017-1708-8

Logroscino, G., Traynor, B. J., Hardiman, O., Chiò, A., Mitchell, D., Swingler, R. J., Millul, A., Benn, E., & Beghi, E. (2009). Incidence of amyotrophic lateral sclerosis in Europe. Journal of Neurology Neurosurgery & Psychiatry, 81(4), 385–390. https://doi.org/10.1136/jnnp.2009.183525

Puopolo, M., Bacigalupo, I., Piscopo, P., Lacorte, E., Di Pucchio, A., Santarelli, M., Inghilleri, M., Petrucci, A., Sabatelli, M., & Vanacore, N. (2021). Prevalence of amyotrophic lateral sclerosis in Latium region, Italy. Brain and Behavior, 11(12). https://doi.org/10.1002/brb3.2378

Longinetti, E., & Fang, F. (2019). Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Current Opinion in Neurology, 32(5), 771–776. https://doi.org/10.1097/wco.0000000000000730

Incidence of ALS in Italy. (2001b). Neurology, 56(2), 239–244. https://doi.org/10.1212/wnl.56.2.239

Arthur, K. C., Calvo, A., Price, T. R., Geiger, J. T., Chiò, A., & Traynor, B. J. (2016b). Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nature Communications, 7(1). https://doi.org/10.1038/ncomms12408




DOI: http://dx.doi.org/10.52155/ijpsat.v45.2.6510

Refbacks



Copyright (c) 2024 Savitran Eshwar, Netra Agarwal

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.